20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Detection of interferon alpha protein reveals differential levels and cellular sources in disease

      research-article
      1 , 3 , 5 , 3 , 5 , 6 , 7 , 8 , 3 , 5 , 6 , 7 , 10 , 11 , 15 , 12 , 13 , 16 , 2 , 13 , 8 , 9 , 12 , 1 , 12 , 17 , 18 , 1 , 11 , 19 , 20 , 21 , 22 , 17 , 2 , 11 , 17 , 7 , 7 , 2 , 15 , 1 , 2 , 11 , 15 , 23 , 24 , 25 , 3 , 4 , 5 , 26 , 1 , 2 , 8 , 14 , 3 , 4 , 5
      The Journal of Experimental Medicine
      The Rockefeller University Press
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rodero et al. report the direct quantification of IFNα protein in monogenic interferonopathies, autoimmunity, and infectious disease states, made possible by the combination of digital ELISA and high-affinity autoantibodies isolated from APECED patients, revealing differential levels and cellular sources dependent on underlying pathology.

          Abstract

          Type I interferons (IFNs) are essential mediators of antiviral responses. These cytokines have been implicated in the pathogenesis of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monogenic type I interferonopathies. Despite a fundamental role in health and disease, the direct quantification of type I IFNs has been challenging. Using single-molecule array (Simoa) digital ELISA technology, we recorded attomolar concentrations of IFNα in healthy donors, viral infection, and complex and monogenic interferonopathies. IFNα protein correlated well with functional activity and IFN-stimulated gene expression. High circulating IFNα levels were associated with increased clinical severity in SLE patients, and a study of the cellular source of IFNα protein indicated disease-specific mechanisms. Measurement of IFNα attomolar concentrations by digital ELISA will enhance our understanding of IFN biology and potentially improve the diagnosis and stratification of pathologies associated with IFN dysregulation.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          The nature of the principal type 1 interferon-producing cells in human blood.

          Interferons (IFNs) are the most important cytokines in antiviral immune responses. "Natural IFN-producing cells" (IPCs) in human blood express CD4 and major histocompatibility complex class II proteins, but have not been isolated and further characterized because of their rarity, rapid apoptosis, and lack of lineage markers. Purified IPCs are here shown to be the CD4(+)CD11c- type 2 dendritic cell precursors (pDC2s), which produce 200 to 1000 times more IFN than other blood cells after microbial challenge. pDC2s are thus an effector cell type of the immune system, critical for antiviral and antitumor immune responses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview

            In this review paper, Rodero and Crow outline the current understanding of the type I interferonopathies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Immune interferon in the circulation of patients with autoimmune disease.

              The observation that type II, or immune, interferon could be produced by peripheral-blood leukocytes in vitro on an immune-specific basis suggested that it also might be produced in vivo in various autoimmune disorders. We found immune interferon in the serums of patients with systemic lupus erythematosus, rheumatoid arthritis, scleroderma and Sjögren's syndrome. Among 28 patients with systemic lupus erythematosus, 71 per cent of those with active and 21 per cent of those with inactive disease showed interferon in their serums. Serial serum samples showed a good correlation between interferon titers and disease activity. Moreover, interferon titers correlated positively with antibodies to DNA and negatively with serum levels of the third component of complement. It is possible that the production of interferon may contribute to immunologic aberrations in auto-immune diseases and also protect the already compromised host from viral infections.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                1 May 2017
                : 214
                : 5
                : 1547-1555
                Affiliations
                [1 ]Laboratory of Neurogenetics and Neuroinflammation, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1163, Institut Imagine, 75015 Paris, France
                [2 ]Université Paris Descartes, Université Sorbonne Paris Cité, Institut Imagine, 75015 Paris, France
                [3 ]Immunobiology of Dendritic Cells, Institut Pasteur, 75015 Paris, France
                [4 ]Centre for Translational Research, Institut Pasteur, 75015 Paris, France
                [5 ]INSERM U1223, 75015 Paris, France
                [6 ]Medical Research Council (MRC) Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH8 9YL, Scotland, UK
                [7 ]Centre for Clinical Brain Sciences (CCBS), University of Edinburgh, Edinburgh EH8 9YL, Scotland, UK
                [8 ]Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9NT, England, UK
                [9 ]Manchester Centre for Genomic Medicine, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9NT, England, UK
                [10 ]Laboratoire d’Immunologie Biologique, Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
                [11 ]Pediatric Immunology-Hematology and Rheumatology Unit, Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
                [12 ]Department of Paediatric Neurology, Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
                [13 ]Department of Paediatric Dermatology, Reference Centre for Rare Skin Disorders (MAGEC), Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
                [14 ]Département de Génétique, Assistance Publique–Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France
                [15 ]Laboratory of Immunogenetics of Pediatric Autoimmunity, INSERM UMR 1163, 75015 Paris, France
                [16 ]Department of Paediatric Rheumatology, Hospices Civils de Lyon, INSERM U1111, 69007 Lyon, France
                [17 ]Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
                [18 ]Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, Netherlands
                [19 ]General Paediatrics, Infectious Disease and Internal Medicine Department, Assistance Publique–Hôpitaux de Paris, Robert-Debré Hospital, 75019 Paris, France
                [20 ]Department of Pediatrics, University Hospitals Leuven, 3000 Leuven, Belgium
                [21 ]Department of Microbiology and Immunology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
                [22 ]Department of Immunology, Assistance Publique–Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, 75013 Paris, France
                [23 ]ImmunoQure AG, 42012 Düsseldorf, Germany
                [24 ]Peter Gorer Department of Immunobiology, King’s College, Guy’s Hospital, London SE1 9RT, England, UK
                [25 ]Francis Crick Institute, London NW1 1BF, England, UK
                [26 ]Service de Virologie, Université Paris Descartes, Université Sorbonne Paris Cité, Assistance–Publique Hôpitaux de Paris, Groupe Hospitalier Universitaire Paris Centre, 75014 Paris, France
                Author notes
                Correspondence to Yanick J. Crow: yanickcrow@ 123456mac.com ; or Darragh Duffy: darragh.duffy@ 123456pasteur.fr
                [*]

                M.P. Rodero, J. Decalf, V. Bondet, and D. Hunt contributed equally to this paper.

                [**]

                Y.J. Crow and D. Duffy contributed equally to this paper.

                Author information
                http://orcid.org/0000-0002-1113-6128
                http://orcid.org/0000-0002-6534-0984
                http://orcid.org/0000-0003-4230-0207
                http://orcid.org/0000-0002-0077-0991
                http://orcid.org/0000-0001-8476-8196
                http://orcid.org/0000-0001-5208-2691
                http://orcid.org/0000-0002-2798-9141
                http://orcid.org/0000-0002-1742-3590
                http://orcid.org/0000-0002-9310-5535
                http://orcid.org/0000-0002-8057-333X
                http://orcid.org/0000-0003-1763-5443
                http://orcid.org/0000-0002-1769-549X
                http://orcid.org/0000-0003-3140-6882
                http://orcid.org/0000-0001-7858-7866
                http://orcid.org/0000-0001-7211-7564
                http://orcid.org/0000-0002-8875-2308
                Article
                20161451
                10.1084/jem.20161451
                5413335
                28420733
                b7c714d0-ed08-49ee-8927-2448504a14e1
                © 2017 Rodero et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 31 August 2016
                : 15 December 2016
                : 02 March 2017
                Funding
                Funded by: European Research Council, DOI http://dx.doi.org/10.13039/100010663;
                Award ID: GA 309449
                Funded by: European Leukodystrophy Association, DOI http://dx.doi.org/10.13039/501100008731;
                Award ID: ELA 2012-008I1
                Funded by: Agence Nationale de la Recherche, DOI http://dx.doi.org/10.13039/501100001665;
                Award ID: ANR-10-IAHU-01
                Funded by: ANR, DOI http://dx.doi.org/10.13039/501100001665;
                Award ID: CE17001002
                Funded by: EU FP7, DOI http://dx.doi.org/10.13039/100011102;
                Award ID: 241779)
                Funded by: PasteurInnov
                Funded by: EU FP7, DOI http://dx.doi.org/10.13039/100011102;
                Award ID: 261365
                Funded by: Lupus UK
                Funded by: Wellcome Trust, DOI http://dx.doi.org/10.13039/100004440;
                Award ID: 106292/Z/14/Z
                Funded by: ANR, DOI http://dx.doi.org/10.13039/501100001665;
                Award ID: ANR-14-CE14-0026-01 “Lumugene”
                Funded by: Wellcome Trust, DOI http://dx.doi.org/10.13039/100004440;
                Categories
                Research Articles
                Technical Advances
                312
                300
                316

                Medicine
                Medicine

                Comments

                Comment on this article